Scholar Rock (NASDAQ:SRRK) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Scholar Rock (NASDAQ:SRRK) in a report released on Thursday morning, Marketbeat reports. The brokerage issued an overweight rating on the stock.

A number of other analysts have also commented on SRRK. Lifesci Capital raised Scholar Rock to a “strong-buy” rating in a research note on Tuesday, June 3rd. Wedbush reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Wednesday, June 18th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Scholar Rock currently has a consensus rating of “Buy” and a consensus price target of $42.67.

Scholar Rock Price Performance

Shares of NASDAQ SRRK opened at $40.72 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.25 and a quick ratio of 10.25. The stock has a fifty day moving average price of $33.76 and a 200 day moving average price of $35.06. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98. The company has a market cap of $3.87 billion, a PE ratio of -16.09 and a beta of 0.33.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period in the previous year, the firm posted ($0.59) earnings per share. Sell-side analysts forecast that Scholar Rock will post -2.42 EPS for the current year.

Insider Buying and Selling

In other Scholar Rock news, Director Joshua Reed sold 5,400 shares of the company’s stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $29.72, for a total value of $160,488.00. Following the transaction, the director directly owned 15,732 shares of the company’s stock, valued at $467,555.04. This represents a 25.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Akshay Vaishnaw sold 6,750 shares of the company’s stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $29.72, for a total value of $200,610.00. Following the sale, the insider directly owned 616,205 shares in the company, valued at approximately $18,313,612.60. This represents a 1.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,654 shares of company stock worth $3,265,961 over the last 90 days. 13.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Scholar Rock by 42.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 135,231 shares of the company’s stock valued at $5,845,000 after purchasing an additional 40,436 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Scholar Rock by 3,824.9% during the first quarter. GAMMA Investing LLC now owns 30,928 shares of the company’s stock valued at $962,000 after purchasing an additional 30,140 shares in the last quarter. Vanguard Group Inc. grew its holdings in Scholar Rock by 17.6% during the fourth quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company’s stock worth $205,013,000 after acquiring an additional 708,817 shares during the period. Blackstone Inc. acquired a new position in Scholar Rock during the fourth quarter worth about $910,000. Finally, Raymond James Financial Inc. acquired a new position in Scholar Rock during the fourth quarter worth about $2,625,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.